Cargando…
Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234132/ https://www.ncbi.nlm.nih.gov/pubmed/35769459 http://dx.doi.org/10.3389/fimmu.2022.894206 |
_version_ | 1784735988562526208 |
---|---|
author | Zhang, Xin Sang, Shuli Guan, Qing Tao, Haoxia Wang, Yanchun Liu, Chunjie |
author_facet | Zhang, Xin Sang, Shuli Guan, Qing Tao, Haoxia Wang, Yanchun Liu, Chunjie |
author_sort | Zhang, Xin |
collection | PubMed |
description | Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenuated Shigella vector vaccine SH02 expressing the UreB-HspA fusion protein of H. pylori in a mouse model. Oral SH02 with or without subcutaneous injection of rUreB-HspA induced antigen-specific serum IgG, mucosal sIgA, and T cells immune response. Subcutaneous injection of the candidate antigen rUreB-HspA enhanced the level of serum antigen-specific IgG antibodies (p < 0.0001) and the levels of IgG1/IgG2a/IgG2b subtypes. In addition, injection boost also increased the proportion of spleen antigen-specific CD4+CD154+ T cells (p < 0.001), and the proportion of CD4+CD154+ T cells that secrete IFN-γ and IL-17A. Following the H. pylori challenge, the levels of H. pylori colonization in the two experimental groups (Groups A and B) significantly reduced compared with the control group (p < 0.001), indicating that the candidate vaccine yielded a preventive effect of anti-H.pylori infection. Compared with the non-subcutaneous booster injection group (Group A), the subcutaneous booster injection group (Group B) exhibited less gastric inflammation, but there was no significant difference in the level of colonization (p > 0.05). These results lay a foundation for the development of a vaccine against H. pylori and the optimization of immunization methods and procedures to prevent H. pylori infection. |
format | Online Article Text |
id | pubmed-9234132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92341322022-06-28 Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model Zhang, Xin Sang, Shuli Guan, Qing Tao, Haoxia Wang, Yanchun Liu, Chunjie Front Immunol Immunology Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenuated Shigella vector vaccine SH02 expressing the UreB-HspA fusion protein of H. pylori in a mouse model. Oral SH02 with or without subcutaneous injection of rUreB-HspA induced antigen-specific serum IgG, mucosal sIgA, and T cells immune response. Subcutaneous injection of the candidate antigen rUreB-HspA enhanced the level of serum antigen-specific IgG antibodies (p < 0.0001) and the levels of IgG1/IgG2a/IgG2b subtypes. In addition, injection boost also increased the proportion of spleen antigen-specific CD4+CD154+ T cells (p < 0.001), and the proportion of CD4+CD154+ T cells that secrete IFN-γ and IL-17A. Following the H. pylori challenge, the levels of H. pylori colonization in the two experimental groups (Groups A and B) significantly reduced compared with the control group (p < 0.001), indicating that the candidate vaccine yielded a preventive effect of anti-H.pylori infection. Compared with the non-subcutaneous booster injection group (Group A), the subcutaneous booster injection group (Group B) exhibited less gastric inflammation, but there was no significant difference in the level of colonization (p > 0.05). These results lay a foundation for the development of a vaccine against H. pylori and the optimization of immunization methods and procedures to prevent H. pylori infection. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234132/ /pubmed/35769459 http://dx.doi.org/10.3389/fimmu.2022.894206 Text en Copyright © 2022 Zhang, Sang, Guan, Tao, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Xin Sang, Shuli Guan, Qing Tao, Haoxia Wang, Yanchun Liu, Chunjie Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title | Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title_full | Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title_fullStr | Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title_full_unstemmed | Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title_short | Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model |
title_sort | oral administration of a shigella 2at32-based vaccine expressing ureb-hspa fusion antigen with and without parenteral rureb-hspa boost confers protection against helicobacter pylori in mice model |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234132/ https://www.ncbi.nlm.nih.gov/pubmed/35769459 http://dx.doi.org/10.3389/fimmu.2022.894206 |
work_keys_str_mv | AT zhangxin oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel AT sangshuli oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel AT guanqing oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel AT taohaoxia oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel AT wangyanchun oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel AT liuchunjie oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel |